ImmunityBio, Inc. is reported to be majority-controlled by Patrick Soon-Shiong and affiliated entities. They beneficially own 745,518,285 shares of common stock, representing 64.8% of the class, based on the issuer’s share counts as of July 31, 2026.
Key reporting entities include Cambridge Equities, LP with 261,705,814 shares (24.7%), Nant Capital, LLC with 339,465,528 shares (29.6%), California Capital Equity, LLC with 106,511,412 shares (10.0%), and NantWorks, LLC with 98,535,253 shares (9.3%). Several entities and Dr. Soon-Shiong also hold rights to acquire additional shares within 60 days through stock options and a convertible promissory note, and the structure involves multiple wholly owned and majority-owned subsidiaries through which voting and dispositive power is shared.
Positive
None.
Negative
None.
Key Figures
Aggregate beneficial ownership:745,518,285 sharesOwnership percentage:64.8 %Cambridge Equities stake:261,705,814 shares+4 more
7 metrics
Aggregate beneficial ownership745,518,285 sharesCommon shares beneficially owned by Patrick Soon-Shiong and affiliated entities; 64.8% of class
Ownership percentage64.8 %Percentage of ImmunityBio common stock beneficially owned by Patrick Soon-Shiong and related entities
Cambridge Equities stake261,705,814 sharesImmunityBio common shares beneficially owned by Cambridge Equities, LP; 24.7% of class
Nant Capital stake339,465,528 sharesShares beneficially owned by Nant Capital, LLC, including 88,446,655 acquirable via promissory note; 29.6% of class
California Capital stake106,511,412 sharesImmunityBio shares beneficially owned by California Capital Equity, LLC; 10.0% of class
NantWorks stake98,535,253 sharesImmunityBio shares beneficially owned by NantWorks, LLC; 9.3% of class
Shares outstanding1,059,836,273 sharesImmunityBio common shares issued and outstanding as of July 31, 2026
"Aggregate amount beneficially owned by each reporting person 745,518,285.00"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Shared Voting Powerfinancial
"Shared Voting Power 713,301,080.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Shared Dispositive Powerfinancial
"Shared Dispositive Power 261,705,814.00"
Nominating Agreementfinancial
"Nominating Agreement by and between the Issuer and Cambridge Equities, LP"
Registration Rights Agreementfinancial
"Registration Rights Agreement by and between the Issuer and Cambridge Equities, LP"
A registration rights agreement is a contract that gives investors the option to have their ownership stakes officially registered with the government, making it easier to sell their shares later. This agreement matters because it provides investors with a clearer path to cash out their investments if they choose, offering more liquidity and confidence in their ability to sell their holdings when desired.
What percentage of ImmunityBio (IBRX) does Patrick Soon-Shiong beneficially own?
Patrick Soon-Shiong beneficially owns 64.8% of ImmunityBio’s common stock, or 745,518,285 shares. This total includes shares he holds directly, stock options exercisable within 60 days, and holdings or rights to acquire shares through controlled entities such as Cambridge Equities and Nant Capital.
How many ImmunityBio (IBRX) shares does Cambridge Equities, LP hold?
Cambridge Equities, LP beneficially owns 261,705,814 shares of ImmunityBio common stock, representing 24.7% of the class. This percentage is based on 1,059,836,273 shares issued and outstanding as of July 31, 2026, as provided by ImmunityBio.
What is Nant Capital, LLC's beneficial ownership in ImmunityBio (IBRX)?
Nant Capital, LLC beneficially owns 339,465,528 ImmunityBio shares, or 29.6% of the class. This includes 251,018,873 shares held directly and 88,446,655 shares that Nant Capital has the right to acquire within 60 days through conversion of a promissory note.
How many ImmunityBio (IBRX) shares are outstanding as of July 31, 2026?
ImmunityBio (IBRX) reports 1,059,836,273 shares of common stock issued and outstanding as of July 31, 2026. This share count is used as the denominator in calculating ownership percentages for several reporting entities and in part of Patrick Soon-Shiong’s aggregate beneficial ownership.
What ImmunityBio (IBRX) stake is attributed to California Capital Equity, LLC and related entities?
California Capital Equity, LLC beneficially owns 106,511,412 shares of ImmunityBio, or 10.0% of the class. NantWorks is a wholly owned subsidiary of California Capital, and NantBio, NantMobile and NCSC are majority-owned by NantWorks, with California Capital sharing voting and dispositive power over their holdings.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 13)
ImmunityBio, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
45256X103
(CUSIP Number)
Charles Kenworthy Cambridge Equities, LP,
450 Duley Road El Segundo,
CA,
90245 (310) 836-6400
Martin J. Waters Wilson Sonsini Goodrich & Rosati,
12235 El Camino Real San Diego,
CA,
92130 (858) 350-2300
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
07/31/2026
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the
Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
schemaVersion:
SCHEDULE 13D
CUSIP Number(s):
45256X103
1
Name of reporting person
Cambridge Equities, LP
2
Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
3
SEC use only
4
Source of funds (See Instructions)
AF, WC, OO
5
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6
Citizenship or place of organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
7
Sole Voting Power
0.00
8
Shared Voting Power
261,705,814.00
9
Sole Dispositive Power
0.00
10
Shared Dispositive Power
261,705,814.00
11
Aggregate amount beneficially owned by each reporting person
261,705,814.00
12
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13
Percent of class represented by amount in Row (11)
24.7 %
14
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person:
The percentage shown in (13) is calculated based upon (x) 261,705,814 shares of the Issuer's Common Stock held by Cambridge Equities, LP ("Cambridge"), divided by (y) 1,059,836,273 shares of the Issuer's Common Stock issued and outstanding, as of July 31, 2026 as provided by the Issuer.
SCHEDULE 13D
CUSIP Number(s):
45256X103
1
Name of reporting person
MP 13 Ventures, LLC
2
Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
3
SEC use only
4
Source of funds (See Instructions)
AF
5
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6
Citizenship or place of organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
7
Sole Voting Power
0.00
8
Shared Voting Power
261,705,814.00
9
Sole Dispositive Power
0.00
10
Shared Dispositive Power
261,705,814.00
11
Aggregate amount beneficially owned by each reporting person
261,705,814.00
12
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13
Percent of class represented by amount in Row (11)
24.7 %
14
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person:
The percentage shown in (13) is calculated based upon (x) 261,705,814 shares of the Issuer's Common Stock held by Cambridge, divided by (y) 1,059,836,273 shares of the Issuer's Common Stock issued and outstanding, as of July 31, 2026, as provided by the Issuer. MP 13 Ventures, LLC ("MP 13 Ventures") may be deemed to beneficially own, and share voting power and investment power with Cambridge over, all shares of the Issuer's Common Stock beneficially owned by Cambridge.
SCHEDULE 13D
CUSIP Number(s):
45256X103
1
Name of reporting person
NantWorks, LLC
2
Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
3
SEC use only
4
Source of funds (See Instructions)
OO
5
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6
Citizenship or place of organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
7
Sole Voting Power
0.00
8
Shared Voting Power
98,535,253.00
9
Sole Dispositive Power
0.00
10
Shared Dispositive Power
98,535,253.00
11
Aggregate amount beneficially owned by each reporting person
98,535,253.00
12
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13
Percent of class represented by amount in Row (11)
9.3 %
14
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person:
The percentage shown in (13) is calculated based upon (x) the sum of (i) 9,986,920 shares of the Issuer's Common Stock held by NantWorks, LLC ("NantWorks"); (ii) 8,383,414 shares of the Issuer's Common Stock held by NantBio, Inc. ("NantBio"); (iii) 47,557,934 shares of the Issuer's Common Stock held by NantMobile, LLC ("NantMobile"); and (iv) 32,606,985 shares of the Issuer's Common Stock held by NantCancerStemCell, LLC ("NCSC") divided by (y) 1,059,836,273 shares of the Issuer's Common Stock issued and outstanding, as of July 31, 2026, as provided by the Issuer. NantBio, NantMobile and NCSC are majority-owned subsidiaries of NantWorks, and NantWorks shares voting and dispositive power over the shares beneficially owned by NantBio, NantMobile, and NCSC. NantWorks disclaims beneficial ownership of the shares of the Issuer's Common Stock beneficially owned by NantBio, NantMobile and NCSC, except to the extent of their pecuniary interest.
SCHEDULE 13D
CUSIP Number(s):
45256X103
1
Name of reporting person
Nant Capital, LLC
2
Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
3
SEC use only
4
Source of funds (See Instructions)
OO
5
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6
Citizenship or place of organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
7
Sole Voting Power
0.00
8
Shared Voting Power
339,465,528.00
9
Sole Dispositive Power
0.00
10
Shared Dispositive Power
339,465,528.00
11
Aggregate amount beneficially owned by each reporting person
339,465,528.00
12
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13
Percent of class represented by amount in Row (11)
29.6 %
14
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person:
The percentage shown in (13) is calculated based upon (x) the sum of (i) 251,018,873 shares of the Issuer's Common Stock held by Nant Capital, LLC ("Nant Capital"); and (ii) 88,446,655 shares of the Issuer's Common Stock that Nant Capital has the right to acquire from the Issuer within 60 days of July 31, 2026 pursuant to the conversion of a promissory note divided by (y) the sum of (i) 1,059,836,273 shares of the Issuer's Common Stock issued and outstanding, as of July 31, 2026, as provided by the Issuer; and (ii) 88,446,655 shares of the Issuer's Common Stock that Nant Capital has the right to acquire from the Issuer within 60 days of July 31, 2026 pursuant to the conversion of a promissory note.
SCHEDULE 13D
CUSIP Number(s):
45256X103
1
Name of reporting person
California Capital Equity, LLC
2
Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
3
SEC use only
4
Source of funds (See Instructions)
OO
5
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6
Citizenship or place of organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
7
Sole Voting Power
0.00
8
Shared Voting Power
106,511,412.00
9
Sole Dispositive Power
0.00
10
Shared Dispositive Power
106,511,412.00
11
Aggregate amount beneficially owned by each reporting person
106,511,412.00
12
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13
Percent of class represented by amount in Row (11)
10.0 %
14
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person:
The percentage shown in (13) is calculated based upon (x) the sum of (i) 7,976,159 shares of the Issuer's Common Stock held by California Capital Equity, LLC ("California Capital"); (ii) 9,986,920 shares of the Issuer's Common Stock held by NantWorks; (iii) 8,383,414 shares of the Issuer's Common Stock held by NantBio; (iv) 47,557,934 shares of the Issuer's Common Stock held by NantMobile; and (v) 32,606,985 shares of the Issuer's Common Stock held by NCSC divided by (y) 1,059,836,273 shares of the Issuer's Common Stock issued and outstanding, as of July 31, 2026, as provided by the Issuer. NantWorks is a wholly-owned subsidiary of California Capital. NantBio, NantMobile and NCSC are majority-owned subsidiaries of NantWorks. California Capital shares voting and dispositive power over the shares beneficially owned by NantWorks, NantBio, NantMobile, and NCSC. California Capital disclaims beneficial ownership of the shares of the Issuer's Common Stock beneficially owned by NantWorks, NantBio, NantMobile and NCSC, except to the extent of their pecuniary interest.
SCHEDULE 13D
CUSIP Number(s):
45256X103
1
Name of reporting person
Patrick Soon-Shiong
2
Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
3
SEC use only
4
Source of funds (See Instructions)
AF, PF, OO
5
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6
Citizenship or place of organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
7
Sole Voting Power
32,217,205.00
8
Shared Voting Power
713,301,080.00
9
Sole Dispositive Power
32,217,205.00
10
Shared Dispositive Power
713,301,080.00
11
Aggregate amount beneficially owned by each reporting person
745,518,285.00
12
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13
Percent of class represented by amount in Row (11)
64.8 %
14
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person:
The percentage in (13) is calculated based upon (x) the sum of (i) 29,757,911 shares of the Issuer's Common Stock held by Dr. Patrick Soon-Shiong; (ii) 2,459,294 shares of the Issuer's Common Stock that Dr. Soon-Shiong has the right to acquire from the Issuer within 60 days of July 31, 2026 pursuant to the exercise of stock options that were exercisable as of July 31, 2026; (iii) 261,705,814 shares of the Issuer's Common Stock held by Cambridge; (iv) 7,976,159 shares of the Issuer's Common Stock held by California Capital; (v) 9,986,920 shares of the Issuer's Common Stock held by NantWorks; (vi) 251,018,873 shares of the Issuer's Common Stock held by Nant Capital; (vii) 88,446,655 shares of the Issuer's Common Stock that Nant Capital has the right to acquire from the Issuer within 60 days of July 31, 2026 pursuant to the conversion of a promissory note; (viii) 8,383,414 shares of the Issuer's Common Stock held by NantBio; (ix) 47,557,934 shares of the Issuer's Common Stock held by NantMobile; (x) 32,606,985 shares of the Issuer's Common Stock held by NCSC; and (xi) 5,618,326 shares of the Issuer's Common Stock held by the Chan Soon-Shiong Family Foundation divided by (y) the sum of (i) 1,059,836,273 shares of the Issuer's Common Stock issued and outstanding, as of July 31, 2026, as provided by the Issuer; (ii) 2,459,294 shares of the Issuer's Common Stock that Dr. Soon-Shiong has the right to acquire from the Issuer within 60 days of July 31, 2026 pursuant to the exercise of stock options that were exercisable as of July 31, 2026; and (iii) 88,446,655 shares of the Issuer's Common Stock that Nant Capital has the right to acquire from the Issuer within 60 days of July 31, 2026, pursuant to the conversion of a promissory note. Dr. Soon-Shiong may be deemed to beneficially own, and share voting power and investment power over, all shares of the Issuer's Common Stock beneficially owned by Cambridge, California Capital, NantWorks, NantBio, NantMobile, NCSC, Nant Capital, and the Chan Soon-Shiong Family Foundation. Dr. Soon-Shiong disclaims beneficial ownership of the shares of the Issuer's Common Stock beneficially owned by Cambridge, California Capital, NantWorks, NantBio, NantMobile, NCSC, Nant Capital, and the Chan Soon-Shiong Family Foundation, except to the extent of his pecuniary interest.
SCHEDULE 13D
Item 1.
Security and Issuer
(a)
Title of Class of Securities:
Common Stock, par value $0.0001 per share
(b)
Name of Issuer:
ImmunityBio, Inc.
(c)
Address of Issuer's Principal Executive Offices:
3530 John Hopkins Court, San Diego,
CALIFORNIA
, 92121.
Item 7.
Material to be Filed as Exhibits.
The following documents are filed as exhibits: Exhibit 99.1 Joint Filing Agreement, dated as of September 21, 2023, by and among Cambridge Equities, LP, MP 13 Ventures, LLC, NantWorks, LLC, NantMobile, LLC, Nant Capital, LLC, California Capital Equity, LLC, and Patrick Soon-Shiong (incorporated by reference to Exhibit 99.1 to the Sch 13D/A (Amendment No. 9) filed with the SEC by the Reporting Persons on September 21, 2023). Exhibit 99.2 Nominating Agreement by and between the Issuer and Cambridge Equities, LP, dated June 18, 2015 (incorporated by reference to Exhibit 4.1 to the Issuer's Registration Statement on Form S-1 (File No. 333-205124) filed with the SEC on June 19, 2015). Registration Rights Agreement by and between the Issuer and Cambridge Equities, LP, dated December 23, 2014 (incorporated by reference to Exhibit 4.3 to the Issuer's Registration Statement on Form S-1 (File No. 333-205124) filed with the SEC on June 19, 2015).
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Cambridge Equities, LP
Signature:
/s/ Charles Kenworthy
Name/Title:
Charles Kenworthy, Manager of MP 13 Ventures, LLC, the General Partner of Cambridge Equities, LP
Date:
08/06/2026
MP 13 Ventures, LLC
Signature:
/s/ Charles Kenworthy
Name/Title:
Charles Kenworthy, Manager
Date:
08/06/2026
NantWorks, LLC
Signature:
/s/ Robert Morse
Name/Title:
Robert Morse, CFO of NantWorks, LLC
Date:
08/06/2026
Nant Capital, LLC
Signature:
/s/ Charles Kenworthy
Name/Title:
Charles Kenworthy, Manager of Nant Capital, LLC
Date:
08/06/2026
California Capital Equity, LLC
Signature:
/s/ Charles Kenworthy
Name/Title:
Charles Kenworthy, Manager of California Capital Equity, LLC
